The role of hepcidin and haemojuvelin in the pathogenesis of iron disorders in patients with severe malnutrition
More details
Hide details
Department of Nutrition and Dietetics, Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, Poland
Department of Pathophysiology, Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, Poland
Ann Agric Environ Med. 2014;21(2):336–338
introduction and objective. The clinical consequences of malnutrition are multi-directional and result in dysfunctions of the majority of internal organs and systems. The results of recent studies suggest that a significant role is played by malnutrition in pathophysiology of iron homeostasis disorders, but the underlying mechanism is unclear. The study describes the potential role of hepcidin and hemojuvelin in the pathogenesis of disorders of iron metabolism during malnutrition. state of knowledge. The participation of hepcidin in regulating iron homeostasis encompasses inhibiting the absorption of food iron from enterocytes and inhibiting the release of stored iron from the reticuloendothelial system cells. One of the factors that increases the post-translational level is the expression of hepcidin is IL-6. In studies focused on malnutrition it was observed that in persons with protein and energy deficits the level of proinflammatory cytokine, i.e. interleukin-6, in the serum, increased. The involvement of haemojuvelin in the overall iron homeostasis is related with the regulation of expression of the hepcidin coding gene on the transcription level. The highest haemojuvelin expression was observed in humans in skeletal muscles. Observations and analyses conducted in vivo allowed the conclusion that soluble HJV and cell-related haemojuvelin regulate hepcidin expression in response to changes in iron concentration. The research also demonstrated that soluble HJV neutralizes the inductive effect of IL-6 action on hepcidin expression. summary. It can be claimed that in persons with protein and/or protein-energetic malnutrition the muscle mass deficit may lead to insufficient production of haemojuvelin and sideropenia.
WHO/NHD/007: Turning the tide of malnutrition: Responding to the challenge of the 21st century. World Health Organization, Geneva 2000.
09Management of severe malnutrition: a manual for physicians and other senior health workers. World Health Organization, Geneva 1999.
DiMaria-Ghalili RA, Amella E. Nutrition in Older Adults: Intervention and assessment can help curb the growing threat of malnutrition. AJN. 2005; 105: 40–50.
Sullivan DH, Bopp MM, Roberson PK. Protein-energy undernutrition and life-threatening complications among the hospitalized elderly. J Gen Intern Med. 2002; 17: 923–932.
Thompson MP, Morris LK. Unexplained weight loss in the ambulatory elderly. J Am Geriatr Soc. 1991; 39: 497–500.
Emery PW. Metabolic changes in malnutrition. Eye. 2005; 19: 1029– 1034.
Evans WJ. Protein nutrition, exercise and aging. J Am Coll Nutr. 2004; 23: 601–609.
Agarwal MB, Mehta BC, Mhaiskar UM, Kumta NB, Shah MD. Effect of malnutrition on iron metabolism – a study of 45 children. J Postgrad Med. 1981; 27: 12–15.
Dülger H, Arik M, Sekeroğlu MR, Tarakçioğlu M, Noyan T, Cesur Y, Balahoroğlu R. Pro-inflammatory cytokines in Turkish children with protein-energy malnutrition. Mediators Inflamm. 2002; 11: 363–365.
Sauerwein RW, Mulder JA, Mulder L, Lowe B, Peshu N, Demacker PN, Meer JW, Marsh K. Inflammatory mediators in children with proteinenergy malnutrition. Am J Clin Nutr. 1997; 65: 1534–1539.
Broxmeyer HE, Lu L, Bicknell DC, Williams DE, Cooper S, Levi S, Salfeld J, Arosio P. The influence of purified recombinant human heavy-subunit and light- subunit ferritins on colony formation in vitro by granulocyte- macrophage and erythroid progenitor cells. Blood. 1986; 68: 1257–1263.
Vreugdenhil G, Nieuwenhuizen C, Swaak AJ. Interactions between erythropoietin and iron metabolism in anaemia of chronic disorders. Eur J Haematol. 1992; 48: 56–57.
Mitrache C, Passweg JR, Libura J, Petrikkos L, Seiler WO, Gratwohl A, Stähelin HB, Tichelli A. Anemia: an indicator for malnutrition in the elderly. Ann Hematol. 2001; 80: 295–298.
Kemna EHJM, Tjalsma H, Podust VN, Swinkels DW. Mass spectrometrybased hepcidin measurements in serum and urine: analytical aspects and clinical implications. Clin Chem. 2007; 53: 620–628.
Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001; 276: 7806–7810.
Hunter HN, Fulton DB, Ganz T, Vogel HJ. The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis. J Biol Chem. 2002; 277: 37597–37603.
Krause A, Neitz S, Magert HJ, Schulz A, Forssmann W-G, SchulzKnappe P, Adermann K. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000; 480: 147–150.
Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DMcV, Ganz T, Kaplan J. Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization. Science. 2004; 306: 2090–2093.
Knutson MD, Oukka M, Koss LM, Aydemir F, Wessling-Resnick M. Iron release from macrophages after erythrophagocytosis is upregulated by ferroportin 1 overexpression and down-regulated by hepcidin. Proc Natl Acad Sci U S A. 2005; 102: 1324–1328.
Domenico I, Ward DM, Kaplan J. Hepcidin regulation: ironing out the details. J Clin Invest. 2007; 117: 1755–1758.
Kemna EHJM, Pickkers P, Nemeth E, van der Hoeven H, Swinkels DW. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood. 2005; 106: 1864–1866.
Lee P, Peng H, Gelbart T, Beutler E. The IL-6- and lipopolysaccharideinduced transcription of hepcidin in HFE-, transferrin receptor 2-, and beta 2-microglobulin-deficient hepatocytes. Proc Natl Acad Sci. 2004; 101: 9263–9265.
Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113: 1271–1276.
Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003; 101: 2461–2463.
Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002; 110: 1037–1044.
Visser M, Pahor M, Taaffe DR, Goodpaster BH, Simonsick EM, Newman AB, Nevitt M, Harris TB. Relationship of interleukin 6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci. 2002; 57: 326–332.
Pietrangelo A, Dierssen U, Valli L, Garuti C, Rump A, Corradini E, Ernst M, Klein C, Trautwein C. STAT3 is required for IL-6-gp130- dependent activation of hepcidin in vivo. Gastroenterology. 2007; 132: 294–300.
Verga Falzacappa MV, Spasic MV, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT-3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood. 2007; 109: 353–358.
Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, Samad TA, Campagna JA, Chung RT, Schneyer AL, Woolf CJ, Andrews NC, Lin HY. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet. 2006; 38: 531–539.
Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest. 2007; 117: 1933–1939.
Lin L, Goldberg YP, Ganz T. Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood. 2005; 106: 2884–2889.
Zhang A-S, Anderson SA, Meyers KR, Hernandez C, Eisenstein RS, Enns CA. Evidence that inhibition of hemojuvelin shedding in response to iron is mediated through neogenin. J Biol Chem. 2007; 282: 12547–12556.